DataMEDS Acquires Helomics from Axe Compute
Analysis based on 11 articles · First reported Sep 15, 2026 · Last updated Sep 16, 2026
The acquisition is a small-cap transaction that significantly boosts DataMEDS' market value and strategic positioning in the oncology diagnostics sector, as reflected by the sharp stock price increase. For Computex, the divestiture allows it to streamline operations and focus on its core AI infrastructure business while retaining exposure to Helomics' future potential.
DataMeds AI, Inc. (NASDAQ:MEDS) completed the acquisition of Helomics Corporation, an artificial intelligence cancer diagnostics laboratory business, from Computex Inc. (NASDAQ:AGPU) for a total purchase value of $1.5 million. The consideration consisted of common shares of DataMEDS and an acquisition note. Through the transaction, DataMEDS acquired Helomics' CLIA/CAP-certified clinical laboratory, all associated equipment, the Predictive Oncology contract research organization central lab services business, and $1.5 million in cash. The acquired business carries no third-party debt requiring repayment and no outstanding unpaid accounts payable outside of ongoing monthly operational expenses. DataMEDS intends to expand Helomics' capabilities beyond tumor molecular profiling and chemosensitivity testing into cancer screening, molecular profiling, traditional CLIA laboratory services, and optimized nutritional support for cancer patients. The acquisition provides DataMEDS with operational capital to support its Health Lives Here campaign and expands its services into cancer management, complementing its existing focus on GLP-1 agonist side effects and Long COVID. Computex, which will retain a shareholder position in Helomics, will focus its resources on scaling its core AI infrastructure business. Helomics was the final operating business remaining from Computex's former identity as Predictive Oncology Inc. prior to its name change in December 2025. Following the announcement, DataMEDS shares surged 87.20% to close at $1.62 on Tuesday, September 16, 2026, while Computex shares advanced 2.74%. DataMEDS recently implemented a 1-for-50 reverse stock split on May 26, 2026, and maintains a market capitalization of approximately $5 million.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard